EXHIBIT 23

	Case 3:16-md-02741-VC Document 192-23 Filed 03/15/17 Page 2 of 37
Message	
From:	KOCH, MICHAEL S [AG/1000] [/O=MONSANTO/OU=NA-1000-01/CN=RECIPIENTS/CN=MSKOCH]
Sent:	9/10/2014 10:48:36 PM
To:	SHERMAN, JAMES [AG/1000] [/O=MONSANTO/OU=NA-1000-01/cn=Recipients/cn=JJSHER2]
CC:	HEYDENS, WILLIAM F [AG/1000] [/O=MONSANTO/OU=NA-1000-01/cn=Recipients/cn=230737]
Subject:	Tier 2 feedback
Attachments:	Rat Carc Tier II MSK.docx; Rat combined chronic-carc example.pdf; 18-month mouse example.pdf; Mouse Carc Tier II
	MSK.docx; 1-year Dog Waiver Draft Final for Canada Review MSK.docx
Hi Jim,	
5	
	tached my feedback on the Tier 2s you've sent me recently. Overall, I think they look good. My main
	at they are too long, but this is a pretty common challenge. In conversations with Kimberly on her Tier 2s
she shared Summary examples from Joel on Acetochlor studies (4-5 pages per study summary). Many of the same types	
	re summarized and I have attached the examples for the rat and mouse chronic/carc studies as a guide on
	ense the information currently in your documents. Based on yesterday's email it looks like you've adopted
	e techniques for the Materials and Methods section, but I think we can shorten them further so we have
concise, impa	octful documents. I imagine we can get them to 6 pages or less.
I have also re	viewed the dog waiver from a fatal flaw perspective. I'd say it is also in good shape, but I would like to
	some of the arguments in the document from a consistency perspective. Accordingly, my comments focus
on that aspec	
on that aspec	.c.
Please let me	know if you have any questions or concerns about my feedback on any of these documents.
Thanks,	
Mike	